![](https://investorshub.advfn.com/uicon/33199.png?cb=1474042454)
Sunday, October 24, 2010 10:55:05 AM
NanoViricides Announces a Herpes Virus Research Agreement With Professor Ken S. Rosenthal of Northeastern Ohio Universities College of Medicine
NanoViricides Inc.Posted on:13 May 10
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal’s laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.
Under this agreement, Dr. Rosenthal and coworkers will evaluate the effectiveness of nanoviricides® drug candidates against Herpes simplex virus 1 (HSV-1). Cell culture models as well as in vivo (animal) studies will be employed for testing the drug candidates. This testing is expected to help the Company develop an effective nanoviricide drug against oral and genital herpes.
Dr. Rosenthal has been involved in the evaluation of HSV vaccines as well as anti-HSV drugs. His laboratory has developed an improved mouse model of skin-infection with HSV to follow the disease progression. This model has been shown to provide highly uniform and reproducible results. A uniform disease pattern including onset of lesions and further progression to zosteriform lesions is observed in all animals in this model. This uniformity makes it an ideal model for comparative testing of various drug candidates which, the Company believes, can be expected to lead to a broad-spectrum anti-HSV antiviral treatment capable of attacking both HSV-1 and HSV-2.
Dr. Rosenthal is a professor of microbiology, immunology and biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM). He is a leading researcher in the field of herpes viruses. His research interests encompass several aspects of how herpes simplex virus (HSV) interacts with the host to cause disease. His research has addressed how HSV infects skin cells and examined viral properties that facilitate its virulence and ability to cause encephalitis. In addition, Dr. Rosenthal has also been studying a viral protein that makes the HSV more virulent by helping the virus to take over the cellular machinery to make copies of its various parts, assemble these parts together into virus particles and release the virus to infect other cells. He is also researching how the human host immune response works against HSV for the development of protective and therapeutic vaccines.
The Company has developed a library of small chemical ligands that bind to the herpes virus envelope proteins. Using these ligands, a number of candidate nanoviricides that are capable of attacking the herpes virus have been developed. The Company believes that these nanoviricide drug candidates mimic the natural, common attachment function by which HSV-1 and HSV-2 bind to the body’s host cells.
The Company has previously reported that some of our nanoviricide anti-HSV drug candidates reduced HSV viral load by as much as 99.99% in certain cell culture studies.
“We are very excited about this association with the Rosenthal Lab,” said Dr. Eugene Seymour, MD, MPH, CEO of the Company, adding, “We will now be able to rapidly evaluate our anti-herpes therapeutics.”
About NEOUCOM
The Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) is a community-based, public institution focused on the interprofessional training of health professionals. Through its educational, research and service mission, NEOUCOM improves the quality of health care in northeast Ohio. The University is a member of the university system of Ohio and its partners include teaching hospitals, community sites and boards of health.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=21777
Would appreciate a follow up on a regular basis on this and ALL other investigators!!
Search Results
There are 3 results for: "Ken S. Rosenthal" in Author
1.
Amphiphilic membranes with controlled mesh dimensions for insulin delivery+
Macromolecular Symposia
Volume 172, Issue 1, July 2001, Pages: 56–66, Joseph P. Kennedy, Gyorgyi Fenyvesi, Richard P. Levy and Ken S. Rosenthal
Article first published online : 30 AUG 2001, DOI: 10.1002/1521-3900(200107)172:1<56::AID-MASY56>3.0.CO;2-D
* Abstract
* PDF(1531K)
http://is.gd/gfXBG
2.
You have full text access to this OnlineOpen article
Flow cytometric evaluation of anti-herpes drugs†
Cytometry
Volume 8, Issue 4, July 1987, Pages: 392–395, Ken S. Rosenthal, Cheryl M. Hodnichak and Jack L. Summers
Article first published online : 8 MAR 2005, DOI: 10.1002/cyto.990080408
* Abstract
* PDF(375K)
* References
http://is.gd/gfXIg
3.
Cell membrane potential changes follow epstein-barr virus binding
Journal of Cellular Physiology
Volume 117, Issue 1, October 1983, Pages: 39–42, Ken S. Rosenthal and Howard M. Shapiro
Article first published online : 4 FEB 2005, DOI: 10.1002/jcp.1041170107
* Abstract
* PDF(513K)
* References
http://is.gd/gfXL8
If NNVC is a scam - I can't see it. Course I'm not as bright a light as some around here - been called a moron and worse by one unnamed expert!!!
![wink](/images/emoticon03.gif)
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM